Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00488605
Other study ID # H-9926-LCH III
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date August 1, 2023
Est. completion date August 1, 2023

Study information

Verified date August 2023
Source University of New Mexico
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

LCH III is an international, multicentric, prospective clinical study comprised of: - a randomized clinical trial for multisystem "RISK" patients and - a randomized clinical trial for multisystem "LOW RISK" patients and - a pilot study for patients with single system MFB and localized "SPECIAL SITES"


Description:

Therapy for "LOW RISK" Patients: The decision as to which research program you will be assigned will be made entirely by chance. The overall time of therapy will be 6 or 12 months as randomly assigned. The research program will be with the drugs Vinblastine and Prednisone. Initial Therapy 1. Prednisone given by mouth three times a day daily as a four-week course, then gradually decreased over 2 more weeks. 2. Vinblastine will be given IV (into a vein) one day a week for 6 weeks. 3. Patients who have no evidence of active disease at this time will proceed to continuation therapy. Patients whose disease response is stable, mixed or worse will receive additional therapy with: 1. Prednisone in 3 divided doses by mouth for 3 days every week, from week 7-12. 2. Vinblastine IV one day a week for 6 more weeks. - If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy 1. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 6 or 12 from start of therapy, as randomized. 2. Vinblastine IV day 1 every 3 weeks until the end of month 6 or 12 from start of therapy, as randomized. Therapy for "SPECIAL SITE" (Multi-focal Bone Involvement) Patients: Treatment consists of an initial treatment of 6 weeks and a continuation treatment. A second course is given only to patients with progressive disease. The overall therapy time period is 6 months. Initial Therapy 4. Prednisone given by mouth three times a day daily as a four-week course, then gradually decreased over 2 more weeks. 5. Vinblastine will be given IV (into a vein) one day a week for 6 weeks. 6. Patients who have no evidence of active disease at this time will proceed to continuation therapy. Patients whose disease response is stable, mixed or worse will receive additional therapy with: 3. Prednisone in 3 divided doses days 1-3 weekly from week 7-12. 4. Vinblastine IV one day a week for 6 more weeks. - If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy 3. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 6. 4. Vinblastine IV day 1 every 3 weeks until the end of month 6. Group 1 "RISK" patients: The primary aim of the study is to compare the therapeutic efficacy of control arm A (PDN+VBL) with the experimental arm B (PDN+VBL+MTX). The primary endpoint is the proportion of non-responder in risk organs to the initial treatment. Non-response to initial therapy is defined as: • death within 12 weeks of initial treatment or - progression (worse) in risk organs at week 6 - lack of response (=intermediate response or progression) in risk organs at week 12 as compared to the status of disease at week 6. If the null hypothesis is true, the two randomized treatment arms are equally effective in terms of non-response. If the alternative hypotheses is true, there is a difference between the two randomized arms in terms of efficacy. Group 2 "LOW RISK" patients: The primary aim of the study is to compare the reactivation free survival rate in initial responders at week 6 with continuation treatment for 6 months (Arm LR 6) versus 12 months (Arm LR 12) in those patients without disease reactivation within the first 6 months. If the null hypothesis is true, the reactivation rate of both randomized arms are equal. If the alternative hypothesis is true, there is a difference between the two arms in terms of reactivation frequency. Therapy for "RISK" Patients: Treatment A will consist of: 7. Initial Therapy 8. Prednisone given by mouth three times a day daily as a four-week course, then gradually decreased over 2 more weeks. 9. Vinblastine will be given IV (into a vein) one day a week for 6 weeks. 10. Patients who have no evidence of active disease at this time will proceed to continuation therapy. Patients whose disease is improved or unchanged will receive additional therapy with: 5. Prednisone in 3 divided doses by mouth for 3 days every week, from week 7-12. 6. Vinblastine IV one day a week for 6 more weeks. ** If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 5. 6-MP by mouth daily until the end of month 12. 6. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. 7. Vinblastine IV day 1 every 3 weeks until the end of month 12. ** Those patients whose disease didn't respond to the initial therapy by the 12th week will come off this study and proceed to other research programs. Treatment B will consist of: 1. Initial Therapy 2. Prednisone given by mouth three times a day daily as a four-week course then gradually decreased over 2 more weeks. 3. Vinblastine will be given IV one day a week for 6 weeks. 4. Methotrexate given as a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin. 5. Leucovorin is a drug that will be given to help the body remove the methotrexate and decrease the possible side effects. (This is sometimes called a "leukovorin rescue". The drug will be given by mouth.) - Patients who have no evidence of active disease at this time will proceed to continuation therapy. Patients whose disease is improved or unchanged will receive additional therapy with: 1. Prednisone in 3 divided doses, days 1-3 weekly from week 7-12. 2. Vinblastine IV one day a week for 6 more weeks. 3. Methotrexate given as a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. - If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 1. 6-MP by mouth daily until the end of month 12. 2. Prednisone in 3 doses daily days 1-5 every 3 weeks until the end of month 12. 3. Vinblastine IV day 1 every 3 weeks until the end of month 12. 4. Methotrexate by mouth once weekly until the end of month 12. Those patients whose disease didn't respond to the initial research program by the 12th week will come off this research study and proceed to another research program.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date August 1, 2023
Est. primary completion date August 1, 2023
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria: All newly diagnosed patients who meet the following criteria are eligible to be enrolled and followed in the study: - Definitive diagnosis of LCH - Age under 18 years - No prior treatment for LCH Exclusion Criteria: - Not specified

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Prednisone, Vinblastin, 6-mercaptopuroine
Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
Leucovorin, Methotrexate, Vinblastine, Prednisone
Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.

Locations

Country Name City State
United States University of New Mexico Albuquerque New Mexico

Sponsors (1)

Lead Sponsor Collaborator
University of New Mexico

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The proportion of non-responder in risk organs to the initial treatment 12 months
Secondary Overall survival 12 months
Secondary Proportion of responders (overall and in risk organs) at week 6
Secondary Proportion of responders (overall and in risk organs) at week 12
Secondary Reactivation free survival after response at week 12
Secondary Time to NAD at weeks 6, 12, 7, or 13-23
See also
  Status Clinical Trial Phase
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Recruiting NCT04092803 - Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu N/A
Active, not recruiting NCT02530463 - Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome Phase 2
Completed NCT00948064 - Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Phase 2
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Recruiting NCT03948529 - RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation Phase 2
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Active, not recruiting NCT02723994 - A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia Phase 2
Terminated NCT02469415 - Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Phase 2
Recruiting NCT04856215 - 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia Phase 2
Recruiting NCT06155188 - Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia N/A
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Completed NCT02910583 - Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) Phase 2
Completed NCT01212926 - Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Recruiting NCT05866887 - Insomnia Prevention in Children With Acute Lymphoblastic Leukemia N/A